Vaxart (VXRT) Expected to Announce Earnings on Thursday

Vaxart (NASDAQ:VXRT - Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Vaxart to post earnings of ($0.10) per share and revenue of $15.68 million for the quarter.

Vaxart Stock Down 0.4 %

NASDAQ:VXRT traded down $0.00 during mid-day trading on Friday, hitting $0.47. 2,358,630 shares of the company traded hands, compared to its average volume of 2,374,171. The stock's fifty day moving average price is $0.69 and its 200-day moving average price is $0.73. Vaxart has a one year low of $0.45 and a one year high of $1.41. The firm has a market cap of $106.87 million, a price-to-earnings ratio of -1.15 and a beta of 1.69.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.